Telomir Pharmaceuticals earnings were -$16.1M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest TELO earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$5.1M, up 132.6% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, TELO reported annual earnings of -$16.5M, with 26.5% growth. The next TELO earnings date is Nov 10, 2025.
Telomir Pharmaceuticals Earnings Reports & History FAQ
What were Telomir Pharmaceuticals's earnings last quarter?
On TELO's earnings call on Invalid Date, Telomir Pharmaceuticals (NASDAQ: TELO) reported Q2 2025 earnings per share (EPS) of -$0.17, up 240% year over year. Total TELO earnings for the quarter were -$5.07 million. In the same quarter last year, Telomir Pharmaceuticals's earnings per share (EPS) was -$0.05.
When does Telomir Pharmaceuticals report earnings?
The next TELO earnings date is Invalid Date. Add TELO to your watchlist to be reminded of Telomir Pharmaceuticals's next earnings date.
Is Telomir Pharmaceuticals profitable or losing money?
As of the last Telomir Pharmaceuticals earnings report, Telomir Pharmaceuticals is currently losing money. Telomir Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$16.14 million, a 13.89% decrease year over year.
What was TELO's earnings growth in the past year?
As of Telomir Pharmaceuticals's earnings date in Invalid Date, Telomir Pharmaceuticals's earnings has grown year over year. TELO earnings in the past year totalled -$16.14 million.
What are Telomir Pharmaceuticals's earnings expectations?
The current EPS estimate for Telomir Pharmaceuticals's earnings report in Invalid Date is -$0.04.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.